28 articles for RM Klabe
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Data
Article Title
Organization
Synthesis and biological activities of potential metabolites of the non-nucleoside reverse transcriptase inhibitor efavirenz.
Dupont Pharmaceuticals
Trifluoromethyl-containing 3-alkoxymethyl- and 3-aryloxymethyl-2-pyridinones are potent inhibitors of HIV-1 non-nucleoside reverse transcriptase.
Dupont Pharmaceuticals
3,3a-Dihydropyrano[4,3,2-de]quinazolin-2(1H)-ones are potent non-nucleoside reverse transcriptase inhibitors.
Dupont Pharmaceuticals
Novel 2,2-dioxide-4,4-disubstituted-1,3-H-2,1,3-benzothiadiazines as non-nucleoside reverse transcriptase inhibitors.
Dupont Pharmaceuticals
Synthesis, antiviral activity and pharmacokinetics of P1/P1' substituted 3-aminoindazole cyclic urea HIV protease inhibitors.
Bristol-Myers Squibb
Unsymmetrical cyclic ureas as HIV-1 protease inhibitors: novel biaryl indazoles as P2/P2' substituents.
Dupont Pharmaceuticals
Increased antiviral activity of cyclic urea HIV protease inhibitors by modifying the P1/P1' substituents.
Dupont Pharmaceuticals
The synthesis and evaluation of cyclic ureas as HIV protease inhibitors: modifications of the P1/P1' residues.
Dupont Pharmaceuticals
Potent cyclic urea HIV protease inhibitors with 3-aminoindazole P2/P2' groups.
Dupont Pharmaceuticals
Nonsymmetric P2/P2' cyclic urea HIV protease inhibitors. Structure-activity relationship, bioavailability, and resistance profile of monoindazole-substituted P2 analogues.
Dupont Pharmaceuticals
Compositions, methods, and systems for the synthesis and use of imaging agents
Lantheus Medical Imaging
Substituted N-heteroaryl spirolactam bipyrrolidines, preparation and therapeutic use thereof
Sanofi
Indolinone based phosphoinositide-dependent kinase-1 (PDK1) inhibitors. Part 2: optimization of BX-517.
Berlex Biosciences
5-chloro-3-(phenylsulfonyl)indole-2-carboxamide: a novel, non-nucleoside inhibitor of HIV-1 reverse transcriptase.
Merck Research Laboratories
Aminodiol HIV protease inhibitors. Synthesis and structure-activity relationships of P1/P1' compounds: correlation between lipophilicity and cytotoxicity.
Bristol-Myers Squibb